NCT02428660 - Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM | Biotech Hunter

Enrollment

341

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Cytochrome P450 CYP2D6 Enzyme DeficiencyPoor Metabolizer Due to Cytochrome P450 CYP2D6 VariantUltrarapid Metabolizer Due to Cytochrome P450 CYP2D6 VariantExtensive Metabolizer Due to Cytochrome P450 CYP2D6 VariantCytochrome P450 CYP2C9 Enzyme DeficiencyCytochrome P450 CYP2C19 Enzyme DeficiencyDrug Metabolism, Poor, CYP2D6-RELATEDDrug Metabolism, Poor, CYP2C19-RELATEDCYP2D6 Polymorphism

Interventions

GENETIC

Pharmacogenetic testing

Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms

OTHER

Software-based drug & gene interaction risk analysis

By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.

OTHER

MTM

Medication Therapy Management

Trial Locations (1)

84109

VRx Pharmacy Services, Salt Lake City